Page 1663 - Williams Hematology ( PDFDrive )

1638 Part XI: Malignant Lymphoid Diseases Chapter 98: Diffuse Large B-Cell Lymphoma and Related Diseases 1639

17. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose 49. DeVita VT Jr, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma, a
clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A potentially curable disease. Lancet 1:7901, 1975.
100:17, 2003. 50. Gaynor ER, Ultmann JE, Golomb HM, Sweet DL: Treatment of diffuse histiocytic lym-
18. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lym- phoma (DHL) with COMLA (cyclophosphamide, Oncovin, methotrexate, leucovorin,
phoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:36, 2008. cytosine arabinoside): A 10-year experience in a single institution. J Clin Oncol 3:12,
19. Morin RD, Johnson NA, Severson TM, et al: Somatic mutations altering EZH2 (Tyr641) 1985.
in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 51. Schein PS, DeVita VT Jr, Hubbard S, et al: Bleomycin, Adriamycin, cyclophosphamide,
42:2, 2010. vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of
20. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying advanced diffuse histiocytic lymphoma. Ann Intern Med 85:4, 1976.
genes in non-Hodgkin lymphoma. Nature 476:7360, 2011. 52. Fisher RI, DeVita VT Jr, Hubbard SM, et al: Diffuse aggressive lymphomas: Increased
21. Morin RD, Mungall K, Pleasance E, et al: Mutational and structural analysis of diffuse survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
large B-cell lymphoma using whole-genome sequencing. Blood 122:7, 2013. Ann Intern Med 98:3, 1983.
22. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signalling in diffuse 53. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation com-
large B-cell lymphoma. Nature 463:7277, 2010. bination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for
23. Ngo VN, Young RM, Schmitz R, et al: Oncogenically active MYD88 mutations in advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327:19, 1992.
human lymphoma. Nature 470:7332, 2011. 54. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP)
24. Aviles A, Neri N, Huerta-Guzman J: Large bowel lymphoma: An analysis of prognostic with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.
factors and therapy in 53 patients. J Surg Oncol 80:2, 2002. N Engl J Med 328:14, 1993.
25. Paryani S, Hoppe RT, Burke JS, et al: Extralymphatic involvement in diffuse non-Hodgkin’s 55. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with
lymphoma. J Clin Oncol 1:11, 1983. CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:4,
26. van Besien K, Ha CS, Murphy S, et al: Risk factors, treatment, and outcome of central 2002.
nervous system recurrence in adults with intermediate-grade and immunoblastic lym- 56. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the
phoma. Blood 91:4, 1998. treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe
27. Doggett RS, Wood GS, Horning S, et al: The immunologic characterization of 95 d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:18, 2005.
nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115:2, 57. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone
1984. or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J
28. Stein H, Lennert K, Feller AC, Mason DY: Immunohistological analysis of human Clin Oncol 24:19, 2006.
lymphoma: Correlation of histological and immunological categories. Adv Cancer Res 58. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly
42:67, 1984. CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell
29. Yamaguchi M, Seto M, Okamoto M, et al: De novo CD5+ diffuse large B-cell lymphoma: lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:2, 2008.
A clinicopathologic study of 109 patients. Blood 99:3, 2002. 59. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus ritux-
30. Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. imab versus CHOP-like chemotherapy alone in young patients with good-prognosis
Blood 111:8, 2008. diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera Inter-
31. Stauder R, Eisterer W, Thaler J, Gunthert U: CD44 variant isoforms in non-Hodgkin’s national Trial (MInT) Group. Lancet Oncol 7:5, 2006.
lymphoma: A new independent prognostic factor. Blood 85:10, 1995. 60. Cunningham D, Hawkes E, Jack A, et al: Rituximab plus cyclophosphamide, doxo-
32. Ottensmeier CH, Stevenson FK: Isotype switch variants reveal clonally related subpop- rubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large
ulations in diffuse large B-cell lymphoma. Blood 96:7, 2000. B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with
33. Cheson B, Pfistner B, Gascoyne R: Revised response criteria for malignant lymphoma. 14-day versus 21-day cycles. Lancet 381:9880, 2013.
J Clin Oncol 25:5, 2007. 61. Delarue R, Tilly H, Mounier N, et al: Dose-dense rituximab-CHOP compared with
34. Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB: Results of radiotherapy in con- standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the
trol of stage I and II non-Hodgkin’s lymphoma. Cancer 43:4, 1979. LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14:6, 2013.
35. Jones SE, Miller TP, Connors JM: Long-term follow-up and analysis for prognostic 62. Recher C, Coiffier B, Haioun C, et al: Intensified chemotherapy with ACVBP plus rituximab
factors for patients with limited-stage diffuse large-cell lymphoma treated with initial versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma
chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7:9, 1989. (LNH03-2B): An open-label randomised phase 3 trial. Lancet 378:9806, 2011.
36. Longo DL, Glatstein E, Duffey PL, et al: Treatment of localized aggressive lymphomas 63. Lai GM, Chen YN, Mickley LA, et al: P-glycoprotein expression and schedule depen-
with combination chemotherapy followed by involved-field radiation therapy. J Clin dence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer
Oncol 7:9, 1989. 49:5, 1991.
37. Monfardini S, Banfi A, Bonadonna G, et al: Improved five year survival after combined 64. Gutierrez M, Chabner BA, Pearson D, et al: Role of a doxorubicin-containing regi-
radiotherapy-chemotherapy for stage I-II non-Hodgkin’s lymphoma. Int J Radiat Oncol men in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH: J Clin
Biol Phys 6:2, 1980. Oncol 18:21, 2000.
38. Nissen NI, Ersboll J, Hansen HS, et al: A randomized study of radiotherapy versus 65. Wilson WH, Bates SE, Fojo A, et al: Controlled trial of dexverapamil, a modulator of
radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphomas. Cancer 52:1, multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol
1983. 13:8, 1995.
39. Tondini C, Zanini M, Lombardi F, et al: Combined modality treatment with primary 66. Wilson WH, Grossbard ML, Pittaluga S, et al: Dose-adjusted EPOCH chemotherapy
CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically for untreated large B-cell lymphomas: A pharmacodynamic approach with high effi-
aggressive non-Hodgkin’s lymphomas. J Clin Oncol 11:4, 1993. cacy. Blood 99:8, 2002.
40. Vokes EE, Ultmann JE, Golomb HM, et al: Long-term survival of patients with local- 67. Wilson WH, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and
ized diffuse histiocytic lymphoma. J Clin Oncol 3:10, 1985. rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center
41. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemo- and post-germinal center biomarkers. J Clin Oncol 26:16, 2008.
therapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s 68. U.S. National Library of Medicine. ClinicalTrials.gov [online] 2014. Available from:
lymphoma. N Engl J Med 339:1, 1998. http://clinicaltrials.gov/show/NCT00118209.
42. Miller TP, Leblanc M, Spier C, et al: CHOP alone compared to CHOP plus radiother- 69. Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplan-
apy for early stage aggressive non-Hodgkin’s lymphomas: Update of the Southwest tation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma:
Oncology Group (SWOG) randomized trial. Blood 98:11, 2001. Updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de
43. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in l’Adulte. J Clin Oncol 15:3, 1997.
limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncol- 70. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al: Standard chemotherapy with
ogy Group study 1484. J Clin Oncol 22:15, 2004. or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: Ran-
44. Bonnet C, Fillet G, Mounier N, et al: CHOP alone compared with CHOP plus radio- domized phase III EORTC study. J Natl Cancer Inst 93:1, 2001.
therapy for localized aggressive lymphoma in elderly patients: A study by the Groupe 71. Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone
d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25:7, 2007. marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a
45. Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for local- prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study
ized aggressive lymphoma. N Engl J Med 352:12, 2005. Group. J Clin Oncol 16:8, 1998.
46. Persky DO, Unger JM, Spier CM, et al: Phase II study of rituximab plus three cycles of 72. Verdonck LF, van Putten WL, Hagenbeek A, et al: Comparison of CHOP chemother-
CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell apy with autologous bone marrow transplantation for slowly responding patients with
lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26:14, 2008. aggressive non-Hodgkin’s lymphoma. N Engl J Med 332:16, 1995.
47. Phan J, Mazloom A, Medeiros J, et al: Benefit of consolidative radiation therapy in 73. Gisselbrecht C, Lepage E, Molina T, et al: Shortened first-line high-dose chemotherapy
patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:10, 2002.
Oncol 28:27, 2010. 74. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-
48. Held G, Murawski N, Ziepert M, et al: Role of radiotherapy to bulky disease in elderly risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87–2
patients with aggressive B-cell lymphoma. J Clin Oncol 31:15, 2014. protocol—A Groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:16, 2000.

Kaushansky_chapter 98_p1625-1640.indd 1638 9/18/15 11:42 PM